This Beer Stock Looks Appetizing

Brittney Barrett |


The recent volatility on Wall Street is making head spin. Mixed earnings alongside dour economic reports have left even the most seasoned analysts hazy on where stocks are headed.  So what to do when the majority of data seems to reveal nothing? Sit back relax and have a drink. Or at least buy shares of a company that sells them. Amid weak guidance from stocks across the sector the most recent earnings report from Anheuser Busch InBev (BUD) sent a very clear message.

Profit for the company added around 26 percent with net profit reaching $1.45 billion against $1.15 billion in the year-ago-period. Sales for the company were up 8.5 percent to $9.95 billion and rose 3.7 percent on an organic basis.

The company expects volume to continue to improvement in the second half of the year, especially in the fourth quarter in spite of the benefit last year’s Soccer World Cup had on earnings.

When the economy sputters, people tend to reach for a  cold one. The recent woes could be expected to drive up profits even more for the next quarter. The company is still weak from the recent downturn, hovering marginally above it’s 52-week lows in spite of the positive news. It has a P/E ratio of 20.06.

 

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
HZKCL Structured Products Corp. 6.375% CorTS for IBM Corp. Deb. Tr n/a n/a n/a 0 Trade
BUD Anheuser-Busch Inbev SA Sponsored ADR (Belgium) 110.86 -0.12 -0.11 930,898 Trade

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Trustify

Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…